**Name of journal: *World Journal of Hepatology***

**ESPS Manuscript NO: 15601**

**Columns: MINIREVIEWS**

**Occult hepatitis B virus infection in Egypt**

Elbahrawy A *et al*. Occult hepatitis B virus infection in Egypt

Ashraf Elbahrawy, Alshimaa Alaboudy, Walid El Moghazy, Ahmed Elwasseif, Ahmed Alashker, Abdallah Mahmoud Abdallah

**Ashraf Elbahrawy, Ahmed Elwasseif, Ahmed Alashker, Abdallah Mahmoud Abdallah,** Department of Internal Medicine, Al-Azhar School of Medicine, Al-Azhar University, Cairo 11884, Egypt

**Alshimaa Alaboudy,** Department of Gastroenterology and Hepatology, University of Alberta, Alberta T6G 2R3, Canada

**Alshimaa Alaboudy,** Department of Tropical Medicine and Gastroenterology, Sohag University, Sohag 11432, Egypt

**Walid El Moghazy,** Department of HPB Surgery and Transplantation, University of Alberta, Alberta T6G 2R3, Canada

**Walid El Moghazy,** Department of Surgery, Sohag University, Sohag 11432, Egypt

**Author contributions:** Elbahrawy A, Alaboudy A, El Moghazy W and Elwasseif A designed and wrote the review; Alashker A and Abdallah MA contributed to analysis and interpretation of data.

**Conflict-of-interest:** None to declare**.**

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to: Ashraf Elbahrawy, Assistant Professor,** Department of Internal Medicine, Al-Azhar School of Medicine, Al-Azhar University, Nasr City, Cairo 11884, Egypt. bahrawy3@hotmail.com

**Telephone:** +20-2-25109140

**Fax:** +20-2-25109140

**Received:** November 29, 2014

**Peer-review started:** December 2, 2014

**First decision:** January 8, 2015

**Revised:** January 27, 2015

**Accepted:** May 8, 2015

**Article in press:**

**Published online:**

**Abstract**

The emerging evidence of the potentially clinical importance of occult hepatitis B virus (HBV) infection (OBI) increases the interest in this topic. OBI may impact in several clinical contexts, which include the possible transmission of the infection, the contribution to liver disease progression, the development of hepatocellular carcinoma (HCC), and the risk of reactivation. There are several articles that have published on OBI in Egyptian populations. A review of MEDLINE database was undertaken for relevant articles to clarify the epidemiology of OBI in Egypt. HBV genotype D is the only detectable genotype among Egyptian OBI patients. Higher rates of OBI reported among Egyptian chronic hepatitis C virus, hemodialysis, children with malignant disorders, and cryptogenic liver disease patients. There is an evidence of OBI reactivation after treatment with chemotherapy. The available data suggested that screening for OBI must be a routine practice in these groups of patients. Further studies needed for better understand of the epidemiology of OBI among Egyptian young generations after the era of hepatitis B vaccination.

**Key words:** Hepatitis B virus; Occult hepatitis B virus infection; Hepatitis C virus; Egypt; Blood donors; Hemodialysis; Hepatitis B virus reactivation

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Hepatitis B virus genotype D is the only detectable genotype among Egyptian occult hepatitis B virus infection (OBI) patients. Higher rates of OBI reported among Egyptian chronic hepatitis C virus, hemodialysis, children with malignant disorders, and cryptogenic liver disease patients. There is an evidence of OBI reactivation after treatment with chemotherapy. The available data suggested that screening for OBI must be a routine practice in these groups of patients. Further studies are needed to understand the epidemiology of OBI among Egyptian young generations after the era of hepatitis B vaccination.

Elbahrawy A*,* Alaboudy A, El Moghazy W, Elwasseif A, Alashker A, Abdallah AM. Occult hepatitis B virus infection in Egypt. *World J Hepatol* 2015; In press

**INTRODUCTION**

The detection of hepatitis B virus (HBV) nucleic acid in the blood or liver of hepatitis B surface antigen (HBsAg) negative patients is called occult HBV infection (OBI). The molecular basis of OBI usually attributed to the long-term persistence viral covalently-closed-circular DNA in the nuclei of the hepatocytes[1,2]. The majority of the OBI cases infected with replication-competent HBV showing strong suppression of replication and gene expression[1]. The causes of this suppression had not yet clarified, although host immune response and epigenetic factors may play crucial roles. As a consequence of HBV suppression, the viral load is very low (usually below 200 IU/mL) or even undetectable in OBI cases[1].

 Patients with OBI can be either seropositive or seronegative. Seropositive OBI is characterized by positivity of anti-hepatitis B core antibody (anti-HBc) with or without the presence of anti-hepatitis B surface antibody (anti-HBs) while the seronegative OBI s characterized by the negativity of both antibodies. Sero-positive OBI constitutes the vast majority of OBI which can be quite explained by the larger proportion of resolved HBV infection[3]. More than 20% of the occult carriers are seronegative for all HBV markers[1,3]. Whether OBI-seronegative persons lack circulating antibodies due to the progressive antibodies disappearance in the years after acute infection resolution or it occurs from the beginning of HBV infection is unknown[1,4]. Similarly, the difference in terms of clinical impact between OBI-seropositive and OBI-seronegative individuals is entirely obscure. What is known that OBI shows long-lasting specific T-cell immune response against HBV epitopes with a profile that is different between these two subsets of individuals? In fact, while ex vivo responses are similarly weak, in vitro T-cell expansion following specific peptide stimulation is more efficient among seropositive OBI cases than seronegative OBI cases[1,5].

 The only reliable diagnostic marker of OBI is HBV-DNA detection. No standardized assays for the detection of OBI in liver tissue are available[1]. It is strongly recommended to utilize a highly sensitive[1] and specific approach, for both blood and liver analysis based on “nested” or “real time” polymerase chain reaction (PCR) techniques. In addition, the use of primers specific for different HBV genomic regions and complementary to highly conserved (genotype shared) nucleotide sequences highly suggested[1]. Anti-HBc should be used, as a less than ideal surrogate marker if highly sensitive HBV-DNA testing is not feasible[1,6].

 Worldwide, the prevalence of OBI is quite variable[7]. This variability depends on the sensitivity of the HBV DNA detection assay, the sample size, and whether it tested in the liver or the serum[8,9]. There is a growing evidence of a positive correlation between prevalence of OBI and the endemicity of HBV infection[1,3]. Hepatitis C virus (HCV) infected patients appear to be a category of individuals with a higher prevalence of occult HBV[1,3]. In particular, HBV-DNA is detectable in about one-third of HBsAg-negative HCV carriers in the Mediterranean countries[1,3]. In addition, it was suggested that OBI is highly prevalent in HCV-infected patients with the advanced liver disease even in areas with less HBV spread[1,10]. Prevalence of OBI appears to be fairly elevated even in patients with the cryptogenic liver disease, particularly in those with cirrhosis[1]. Among blood donors, OBI appears to be a rare occurrence in the western world. It is a frequent incident in the developing countries[1,11]. OBI rate in HB-vaccinated children varies in different risk groups, according to the local incidence of HBV, and irrespective[12] to anti-HBs sero-status.

 The emerging evidence of the potentially considerable clinical importance of occult HBV infection is the main reason for increasing interest in this topic[1]. OBI may impact in several clinical contexts. The possible transmission of the infection[1], the contribution to liver disease progression[13], the development of hepatocellular carcinoma (HCC)[13], and the risk of reactivation are the most relevant contexts[13,14].

In 2013, the Food and Drug Administration (FDA) had drawn attention to the possible fatal risk of hepatitis B reactivation in patients receiving anti-CD20 drugs[2]. HBV reactivation is known to occur with a wide variety of immune-suppressive therapies and may occur in the context of cancer treatment[2], immunosuppressive therapy for autoimmune disease[2] and transplantation. It is a potentially lethal condition and yet is preventable[7].

 HBV reactivation does occur in persons who have anti-HBc[2] with and without anti-HBs and no detectable HBsAg in serum[2]. Among 100 patients undergoing chemotherapy for non-Hodgkins lymphoma, reactivation was noted in 2 of 45 (4%) anti-HBc positive/HBsAg negative patients[2]. In a study[2] from the Brigham and Women’s Hospital in Boston. Sixty-one patients identified with resolved HBV infection before a hematopoietic stem cell transplant (HSCT), (HBsAg negative, anti-HBc positive)[2]. Of these, 12 (20%) developed reverse seroconversion[2, 5]. A recent systematic literature review identified reports of 257 patients with active or recovered HBV infection [2] treated with anti-tumor necrosis factor (TNF)[16]. Reactivation detected in 5% of those who were HBsAg negative but anti-HBc positive[7]. These data hint that all patients undergoing chemotherapy, immunosuppressive therapy[2], HSCT or solid organ transplantation should screen for prior HBV infection[2]. The use of antiviral treatment appears to diminish the risk of severe or fatal reactivation of hepatitis B (HB) infection [2].

 Egypt had a high prevalence of HCV (17.5%)[17] and intermediate endemicity for HBV infection[18]. The rising prevalence of OBI in Egypt is not surprising. Several reports published on OBI in Egyptian populations. We find that it will prudent to enumerate those studies, and review them to clarify the overall prevalence of OBI and determine the size of that problem in Egypt.

**GEOGRAPHIC DISTRIBUTION OF OBI IN EGYPT**

Lehman *et al*[19] were unable to compare the HBV prevalence between Upper and Lower Egypt due to the inadequate number of HBV prevalence studies in Upper Egypt. Similarly, only two studies[11,20] addressed OBI prevalence in Upper Egypt (Table 1). Lower OBI rate (4.1%)[11] reported among Upper Egypt hemodialysis (HD) patients compared with HD patients in Lower Egypt (26.9%)[21]. HCV prevalence was significantly higher in patients from Lower Egypt according to Lehman and Wilson[19], which in turn confirms the positive correlation between HCV and OBI frequencies.

**OBI GENOTYPES AMONG EGYPTIANS**

The genetic background of OBI studied by Raouf *et al*[22]. The researchers recruited only children with cancer and the results pointed out that the incidence of OBI in those patients was 32% (Table 1). All infections were with genotype D, and 5 out of 16 OBI patients showed some mutation in the HBV sequence. Two patients had a mutation in the surface gene, and a third one had mutation with a significant shift from the wild-type genetic sequence and those three mutations were presumed to be the cause of OBI. The remaining two mutations were considered silent and not the cause of OBI. In addition Kishk *et al*[23] concluded that HBV genotype D was the only detectable genotype in Egyptian OBI patients with chronic HCV[24]. Among 53 HBsAg negative patients with hematologic malignancies, 5 of them (9.4%) experienced HBV reactivation. OBI was confirmed in one of them (1.88%) (Table 1), and all five patients had Genotype D1[20]. HBV-DNA detected in 7/24 HBsAg-negative children with symptomatic hepatic dysfunction. The G1896A mutation found in 3/7 (43%) HBsAg-negative children and all classified as genotype D[25]. Classically it had been concluded that HBV genotype D is more common in the Mediterranean area, the Middle East and India[25,26]. The similarity of OBI genotype and the reported HBV genotype in Egypt could support the assumption that OBI infection is part of the natural history of HBV[21] rather than a distinct entity of infection.

**OBI DISTRIBUTION AMONG DIFFERENT AGE GROUPS**

Hepatitis B virus prevalence is decreasing in Egyptian young generations[19], which may attributed to universal HBV vaccination. The average prevalence of HBV in Egyptian adults is 8% while the average prevalence in children is 1.6%[19]. OBI prevalence among Egyptian adults ranges from 0.48%[24] to 58.3%[13], with lower prevalence among blood donors and higher prevalence among chronic liver disease patients (Table 1). Unexpectedly the prevalence of OBI in children was high according to available data. OBI detected in 31%[22], 32.5%[27], 21%[28] of HCV-positive cancer children, thalassemic and children with hematologic malignancy and disorders respectively (Table 1). These high OBI rates could be attributed to the fact that; these studies assessed OBI in children with multiple risks for HBV transmission, includes poly-transfusion and immunosuppression. In addition, many children in these studies were HCV co-infected, which may explain the higher OBI prevalence among tested children. Going with our notion Elrashidy *et al*[12], were unable to detect OBI among HB-vaccinated healthy children (*n* = 107).

**OBI IN HCV EGYPTIAN PATIENTS**

As HBV and HCV share many risk factors and the same transmission routes[26], OBI detection in HCV patients is not surprising. Indeed, El-Sherif *et al*[29] showed that; among HBsAg-negative patients, the number of patients with parenteral antischistosomal therapy (PAT) is significantly higher in anti-HBc-positive HCV-positive patients, compared with anti-HBc-negative HCV-positive patients[29]. They concluded that PAT transmitted both HCV and HBV in many Egyptians. OBI prevalence in Egyptian HCV-positive patients is 1.83 to 38.3% according to the available data[23,30] (Table 1). This wide range of OBI may be related to different study designs as well as different HBV-DNA detection methods. Moreover, it may related to the liver disease severity and the immunity of the studied patients.

 Occult HBV prevalence correlated with the severity of liver disease in HCV patient[1], and it inflicted an adverse impact on HCV outcome[29]. Selim *et al***[**30] found that OBI prevalence was higher among patients with alanine aminotransferase (ALT) flare (63.3%) in contrast with normal ALT patients (13.3%). One hundred chronic HCV patients negative for HBsAg subdivided into two groups according to anti-HBc seroreactivity and tested for OBI by El-Sherif *et al*[29]. Group A included 71 patients positive for anti-HBc and group B included 29 patients negative for anti-HBc. HCV- patients positive for anti-HBc have more severe liver disease compared with anti-HBc negative patients[29]. Although HBV-DNA in the serum detected in 22.5% of anti-HBc-positive chronic HCV patients, it was not detected in any of anti-HBc-negative patients[29]. There was no significant difference in the clinical and laboratory parameters tested, between anti-HBc-positive patients with and without HBV-DNA in the serum[29]. Kishk *et al*[23] examined the difference between HCV-infected and HCV/OBI dually infected patients in terms of proinflammatory markers, and histopathological picture. Although they used small sample size (3 patients) their results highlighted that OBI associated with higher Necro inflammatory markers and worse histopathological picture. A clear example came from El-Ghitany *et al*[31] who compared OBI prevalence between two groups of apparently healthy blood donors, they found no significant difference between OBI prevalence among both HCV-positive (3.2%) and HCV-negative (5.1%) cohorts.

 One cannot perform firm conclusion about the OBI impact on response to HCV antiviral therapy from the available literature data. Two studies, with a small number of OBI patients (6 patients), addressed the impact of OBI on the response of HCV patients to antiviral therapy. Emara *et al*[32] concluded that; detection of OBI in chronic HCV-positive patients (*n* = 3) has no impact on response to combined pegylated interferon/ribavirin therapy. Similarly, Kishk *et al*[15]. 2014 reported OBI patients (*n* = 3) were responsive to combine pegylated interferon / ribavirin therapy after 12 wk.

**OBI IN EGYPTIAN BLOOD DONORS**

Occult HBV infection extensively explored in blood donors[1] where it appears to occur quite rarely in the western world and more frequently in developing countries[33]. According to available data, OBI was detected in 1.26%[34] to 4.16%[31] of Egyptian blood donors (Table 1). The detection rate of OBI in Egyptian HBsAg-negative blood donors, without known anti-HBc serostatus, is relatively low (4.16%)[31]. This rate markedly increased when OBI tested in anti-HBc positive donors (14.3%)[33]. This high rate of OBI among anti-HBc-positive donors is not consistent with the findings of many published studies[35-38], which ranged from 0%-6%. This high prevalence may attributed to the high sensitivity of used assay. Out of five studies, three[24,34,39] used nested PCR. The fourth one[24] used a real time PCR with very low detection limit (3.8 IU/mL) (Table 2), increasing the sensitivity of OBI detection.

 Little data are available about the infectivity of OBI after a blood transfusion, although the overall OBI transmission rate is 28% according to a recent European study[40]. A lower rate detected in a Taiwanese study[41] (18.2%). The lower transmission rate detected among Japanese (3%) may related to exclusion of patients with detectable levels of HBV-DNA in mini pool nucleic acid test and those with high titer anti-HBc, and many recipients were immune[42]. The infectivity of OBI assessed in a small number of Egyptian blood recipients[33], where 11/34 recipients received anti-HBc positive blood, two of them were HBVDNA positive, and none developed post-transfusion hepatitis. Like other Lookback studies; this study reported several difficulties and limitations in addition to the small sample.

 These data indicated that screening Egyptian blood donors for HBsAg only is not safe and the need for additional blood safety measures to reduce post-transfusion HBV transmission. Anti-HBc screening of Egyptian blood donors (in addition to HBsAg) is not practical. It could result in discarding a significant amount of blood, where HBV-DNA not detected in 82.8%[22], 88%[34], 90%[39], 93.7%[24] of HBsAg-negative/anti-HBc-positive blood donors according to available data. On the other hand missing anti-HBc/HBV-DNA-definite units may have serious implication if used in blood transfusion[39]. Based on the high OBI rate among blood donors, we believe that HBV-DNA testing should introduce in Egypt’s blood banks. Whether to test HBV-DNA in a mini pool, in all blood donors or in anti-HBc-positive donors only is debatable and attractive area for research. Similarly, the relatively high OBI rate among Egyptian blood donors justifies further lookback and traceback extensive study of OBI infectivity among blood recipients.

**OBI IN EGYPTIAN THALASSEMIC**

Populations at high risk of parenterally transmitted infection have widely investigated for OBI[16]. Thalassemic, are at increased risk of infectious disease transmission. The prevalence of OBI among Egyptian thalassemic children was found to be 32.5% (26/80)[27] (Table 1). The prevalence of OBI was 0% and 31.4% among Iranian[43] and Indian[44] thalassemic respectively. This variation may mostly related to small samples size.

**OBI IN EGYPTIAN HEMODIALYSIS PATIENTS**

 The OBI prevalence in Egyptian hemodialysis (HD)-patients range from 4.1% to 26.9%[11,21] (Table 1). Studies on HD-patients have provided widely divergent results. The highest OBI prevalence (58%) in HD-patients reported from Spain[45]. The results reported from Turkey varied from Zero to 27.5%[46,47]. Lower prevalence (3.8%) was reported by American investigators[48]. Studies from Greece showed that 0.9%-20.4% of HD-patients suffered from OBI[49,50]. The prevalence of OBI among HD-patients seems to be multi-factorial and could not be explained by one factor. It is not region specific, where different studies reported contradictory results from the same county. The difference in methods sensitivity and specificity in the various studies could be the main cause responsible for the discrepant findings.

 Age, sex, history of hepatitis, blood transfusion, schistosomal antibodies, liver enzymes, and serum albumin level not associated with OBI in Egyptian hemodialysis patients. In addition, no significant differences in the age, duration of hemodialysis, biochemical parameters, and serological markers of HBV, or HBV-DNA between patients with and without HCV infection. In contrast, the presence of HBV-DNA significantly associated with anti-HBc (*P* = 0.003)[11]. These data support the role of anti-HBc as a useful surrogate marker for OBI in HD-patients whenever HBV-DNA testing is not available.

**OBI IN EGYPTIAN CHILDREN WITH HEMATOLOGIC MALIGNANCIES**

Said *et al*[28] and Raouf *et al*[22] tested OBI in children with hematologic malignancies, and the results pointed out that the incidence of OBI in those patients was 21%-32%, respectively (Table 1). The majority of OBI patients were seronegative to anti-HBc which point that anti-HBc is not sufficient to exclude OBI at least in patients with hematologic malignancies. It believed that hematological malignancies associated with an immune deficiency that could preclude the synthesis of anti-HBs and anti-HBc. Another interesting finding is the higher OBI prevalence in HCV-infected patients.

**OBI IN CRYPTOGENIC LIVER DISEASE PATIENTS**

Occult HBV infection is becoming an important disease entity as a cause of liver disease in HBsAg negative patients. OBI diagnosed in 58.3%[13] of Egyptian patients with symptomatic hepatitis (Table 1). Lower OBI frequency (30%) reported by Chemin *et al*[51] among patients with chronic non-A non-E hepatitis in France. This difference may related to the difference of HBV prevalence in general populations of both countries.

**OBI IN EGYPTIAN HCC PATIENTS**

Occult HBV infection may play a direct oncogenic role through both its integration into the host genome and the maintained transcriptional activity. The prevalence of OBI in HBsAg-negative and anti-HBC-negative HCC patients varies among the different population. It ranges from 16% in the United States[52], which has a low prevalence of chronic hepatitis B, to 70% in endemic areas like china[53]. A high rate of OBI was found among Egyptian HCC patients 62.55% (25/40)[54] (Table 1). This high frequency of OBI in Egyptian patients with HCC cannot explain the level of HBV endemicity in Egypt. The small samples size in addition to combined OBI and HCV infection may partially explain the higher OBI frequency among studied HCC patients.

**REACTIVATION OF OBI AFTER CHEMOTHERAPY**

Among 53 patients with hematological malignancies[20], negative for HBsAg before the start of and throughout the chemotherapy course. Thirty-five (66%) were anti-HBc-negative, and the remaining 18 (34%) patients were anti-HBc-positive. Five of the 53 (9.4%) patients with hematologic malignancies experienced HBV reactivation[20], one of them (1.88%) developed reactivation from an occult HBV infection (Table 1).

**ROLE OF HEPATITIS B-VACCINE IN PROTECTION AGAINST OBI**

Because of immune incompetence in diabetic patients compared with healthy control, OBI detected in 11% of diabetic patients *vs.* 3% of healthy controls[55]. Elrashidy *et al*[12] tested the incidence of OBI in HB-vaccinated healthy (*n* = 107) and diabetic (*n* = 63) children. None of the tested children had evidence of OBI or remote HBV infection (anti-HBc) which indicate that HB vaccination had been protective against OBI[12] (Table 1).

**CONCLUSION**

Like HCV and HBV; nationwide epidemiological study providing exact data regarding OBI situation in Egypt is lacking. Our review represented a trial to synthesize the published OBI results in Egypt. The current report highlights the increase in OBI prevalence in Egyptian HCV-positive patients parallel to the progression of liver disease. Screening for OBI in HCV-positive patients may detect those vulnerable to more progression of their liver disease. Further testing of the impact of OBI on HCV antiviral therapy and transplanted patients is needed. In addition screening for OBI must be a routine practice in blood donors and poly transfused as well as cryptogenic liver disease patients. A definitive assessment of OBI among Egyptian blood donors needed for testing all HBsAg-negative blood donors, instead of only testing anti-HBc-positive patients. Further evaluation of the OBI epidemiology among Egyptian young generations after the era of HBV vaccination is needed. As well, studies of OBI in Upper Egypt should be encouraged.

**ACKNOWLEDGMENTS**

Here the authors would like to thank Professor Kouka Saad Eldeen Abdel Wahab, Professor of Virology, Al-Azhar University, Cairo, Egypt, for critical discussion of our review.

**REFERENCES**

1 **Raimondo G**, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. *J Hepatol* 2007; **46**: 160-170 [PMID: 17112622 DOI: 10.1016/j.jhep.2006.10.007]

2 **Levrero M**, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M. Control of cccDNA function in hepatitis B virus infection. *J Hepatol* 2009; **51**: 581-592 [PMID: 19616338 DOI: 10.1016/j.jhep.2009.05.022]

3 **Torbenson M**, Thomas DL. Occult hepatitis B. *Lancet Infect Dis* 2002; **2**: 479-486 [PMID: 12150847]

4 **Michalak TI**, Mulrooney PM, Coffin CS. Low doses of hepadnavirus induce infection of the lymphatic system that does not engage the liver. *J Virol* 2004; **78**: 1730-1738 [PMID: 14747538]

5 **Zerbini A**, Pilli M, Boni C, Fisicaro P, Penna A, Di Vincenzo P, Giuberti T, Orlandini A, Raffa G, Pollicino T, Raimondo G, Ferrari C, Missale G. The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. *Gastroenterology* 2008; **134**: 1470-1481 [PMID: 18355815 DOI: 10.1053/j.gastro.2008.02.017]

6 **Raimondo G**, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, Craxì A, Donato F, Ferrari C, Gaeta GB, Gerlich WH, Levrero M, Locarnini S, Michalak T, Mondelli MU, Pawlotsky JM, Pollicino T, Prati D, Puoti M, Samuel D, Shouval D, Smedile A, Squadrito G, Trépo C, Villa E, Will H, Zanetti AR, Zoulim F. Statements from the Taormina expert meeting on occult hepatitis B virus infection. *J Hepatol* 2008; **49**: 652-657 [PMID: 18715666 DOI: 10.1016/j.jhep.2008.07.014]

7 **Ramezani A**, Banifazl M, Eslamifar A, Sofian M, Aghakhani A. Occult hepatitis B infection in different high risk patients. *Hepat Mon* 2012; **12**: 467-468 [PMID: 23008730 DOI: 10.5812/hepatmon.7094]

8 **Emara MH**. Occult hepatitis B: the Egyptian situation. *Trop Gastroenterol* 2012; **33**: 242-250 [PMID: 23923349]

9 **Shetty K**, Hussain M, Nei L, Reddy KR, Lok AS. Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C. *Liver Transpl* 2008; **14**: 534-540 [PMID: 18324677 DOI: 10.1002/lt.21284]

10 **Elrashidy H**, El-Didamony G, Elbahrawy A, Hashim A, Alashker A, Morsy MH, Elwassief A, Elmestikawy A, Abdallah AM, Mohammad AG, Mostafa M, George NM, Abdelhafeez H. Absence of occult hepatitis B virus infection in sera of diabetic children and adolescents following hepatitis B vaccination. *Hum Vaccin Immunother* 2014; **10**: 2336-2341 [PMID: 25424940 DOI: 10.4161/hv.29521]

11 **Raimondo G**, Pollicino T, Romanò L, Zanetti AR. A 2010 update on occult hepatitis B infection. *Pathol Biol* (Paris) 2010; **58**: 254-257 [PMID: 20303674 DOI: 10.1016/j.patbio.2010.02.003]

12 **Di Bisceglie AM**, Lok AS, Martin P, Terrault N, Perrillo RP, Hoofnagle JH. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? *Hepatology* 2015; **61**: 703-711 [PMID: 25412906 DOI: 10.1002/hep.27609]

13 **Hammond SP**, Borchelt AM, Ukomadu C, Ho VT, Baden LR, Marty FM. Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant* 2009; **15**: 1049-1059 [PMID: 19660717 DOI: 10.1016/j.bbmt.2009.05.001]

14 **Pérez-Alvarez R**, Díaz-Lagares C, García-Hernández F, Lopez-Roses L, Brito-Zerón P, Pérez-de-Lis M, Retamozo S, Bové A, Bosch X, Sanchez-Tapias JM, Forns X, Ramos-Casals M. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. *Medicine* (Baltimore) 2011; **90**: 359-371 [PMID: 22033451 DOI: 10.1097/MD.0b013e3182380a76]

15 **Karoney MJ**, Siika AM. Hepatitis C virus (HCV) infection in Africa: a review. *Pan Afr Med J* 2013; **14**: 44 [PMID: 23560127 DOI: 10.11604/pamj.2013.14.44.2199]

16 **Attia MA**. Prevalence of hepatitis B and C in Egypt and Africa. *Antivir Ther* 1998; **3**: 1-9 [PMID: 10726051]

17 **Lehman EM**, Wilson ML. Epidemiology of hepatitis viruses among hepatocellular carcinoma cases and healthy people in Egypt: a systematic review and meta-analysis. *Int J Cancer* 2009; **124**: 690-697 [PMID: 18973270 DOI: 10.1002/ijc.23937]

18 **Abu El Makarem MA**, Abdel Hamid M, Abdel Aleem A, Ali A, Shatat M, Sayed D, Deaf A, Hamdy L, Tony EA. Prevalence of occult hepatitis B virus infection in hemodialysis patients from egypt with or without hepatitis C virus infection. *Hepat Mon* 2012; **12**: 253-258 [PMID: 22690232 DOI: 10.5812/hepatmon.665]

19 **Elkady A**, Aboulfotuh S, Ali EM, Sayed D, Abdel-Aziz NM, Ali AM, Murakami S, Iijima S, Tanaka Y. Incidence and characteristics of HBV reactivation in hematological malignant patients in south Egypt. *World J Gastroenterol* 2013; **19**: 6214-6220 [PMID: 24115819 DOI: 10.3748/wjg.v19.i37.6214]

20 **Elgohry I**, Elbanna A, Hashad D. Occult hepatitis B virus infection in a cohort of Egyptian chronic hemodialysis patients. *Clin Lab* 2012; **58**: 1057-1061 [PMID: 23163124]

21 **Raouf HE**, Yassin AS, Megahed SA, Ashour MS, Mansour TM. Seroprevalence of occult hepatitis B among Egyptian paediatric hepatitis C cancer patients. *J Viral Hepat* 2015; **22**: 103-111 [PMID: 24754376 DOI: 10.1111/jvh.12260]

22 **Kishk R**, Atta HA, Ragheb M, Kamel M, Metwally L, Nemr N. Genotype characterization of occult hepatitis B virus strains among Egyptian chronic hepatitis C patients. *East Mediterr Health J* 2014; **20**: 130-138 [PMID: 24945562]

23 **Youssef A**, Yano Y, El-Sayed Zaki M, Utsumi T, Hayashi Y. Characteristics of hepatitis viruses among Egyptian children with acute hepatitis. *Int J Oncol* 2013; **42**: 1459-1465 [PMID: 23404231 DOI: 10.3892/ijo.2013.1822]

24 **Kumar GT**, Kazim SN, Kumar M, Hissar S, Chauhan R, Basir SF, Sarin SK. Hepatitis B virus genotypes and hepatitis B surface antigen mutations in family contacts of hepatitis B virus infected patients with occult hepatitis B virus infection. *J Gastroenterol Hepatol* 2009; **24**: 588-598 [PMID: 19207682 DOI: 10.1111/j.1440-1746.2008.05727.x]

25 **Antar W**, El-Shokry MH, Abd El Hamid WA, Helmy MF. Significance of detecting anti-HBc among Egyptian male blood donors negative for HBsAg. *Transfus Med* 2010; **20**: 409-413 [PMID: 20573069 DOI: 10.1111/j.1365-3148.2010.01021.x]

26 **Youssef A**, Yano Y, Utsumi T, abd El-alah EM, abd El-Hameed Ael-E, Serwah Ael-H, Hayashi Y. Molecular epidemiological study of hepatitis viruses in Ismailia, Egypt. *Intervirology* 2009; **52**: 123-131 [PMID: 19468235 DOI: 10.1159/000219385]

27 **Shaker O**, Ahmed A, Abdel Satar I, El Ahl H, Shousha W, Doss W. Occult hepatitis B in Egyptian thalassemic children. *J Infect Dev Ctries* 2012; **6**: 340-346 [PMID: 22505444]

28 **Said ZN**, El-Sayed MH, El-Bishbishi IA, El-Fouhil DF, Abdel-Rheem SE, El-Abedin MZ, Salama II. High prevalence of occult hepatitis B in hepatitis C-infected Egyptian children with haematological disorders and malignancies. *Liver Int* 2009; **29**: 518-524 [PMID: 19192168 DOI: 10.1111/j.1478-3231.2009.01975.x]

29 **El-Sherif A**, Abou-Shady M, Abou-Zeid H, Elwassief A, Elbahrawy A, Ueda Y, Chiba T, Hosney AM. Antibody to hepatitis B core antigen as a screening test for occult hepatitis B virus infection in Egyptian chronic hepatitis C patients. *J Gastroenterol* 2009; **44**: 359-364 [PMID: 19271112 DOI: 10.1007/s00535-009-0020-3]

30 **Selim HS**, Abou-Donia HA, Taha HA, El Azab GI, Bakry AF. Role of occult hepatitis B virus in chronic hepatitis C patients with flare of liver enzymes. *Eur J Intern Med* 2011; **22**: 187-190 [PMID: 21402251 DOI: 10.1016/j.ejim.2010.12.001]

31 **El-Ghitany EM**, Farghaly AG, Hashish MH. Occult hepatitis B virus infection among hepatitis C virus seropositive and seronegative blood donors in Alexandria, Egypt. *J Egypt Public Health Assoc* 2013; **88**: 8-13 [PMID: 23528526 DOI: 10.1097/01.EPX.0000422774.29308.b3]

32 **Emara MH**, El-Gammal NE, Mohamed LA, Bahgat MM. Occult hepatitis B infection in egyptian chronic hepatitis C patients: prevalence, impact on pegylated interferon/ribavirin therapy. *Virol J* 2010; **7**: 324 [PMID: 21083926 DOI: 10.1186/1743-422X-7-324]

33 **El-Zayadi AR**, Ibrahim EH, Badran HM, Saeid A, Moneib NA, Shemis MA, Abdel-Sattar RM, Ahmady AM, El-Nakeeb A. Anti-HBc screening in Egyptian blood donors reduces the risk of hepatitis B virus transmission. *Transfus Med* 2008; **18**: 55-61 [PMID: 18279193 DOI: 10.1111/j.1365-3148.2007.00806.x]

34 **Said ZN**, Sayed MH, Salama II, Aboel-Magd EK, Mahmoud MH, Setouhy ME, Mouftah F, Azzab MB, Goubran H, Bassili A, Esmat GE. Occult hepatitis B virus infection among Egyptian blood donors. *World J Hepatol* 2013; **5**: 64-73 [PMID: 23646231 DOI: 10.4254/wjh.v5.i2.64]

35 **Amini S**, Mahmoodi MF, Andalibi S, Solati AA. Seroepidemiology of hepatitis B, delta and human immunodeficiency virus infections in Hamadan province, Iran: a population based study. *J Trop Med Hyg* 1993; **96**: 277-287 [PMID: 8411302]

36 **Ks M**, R A, P A. The prevalence of the hepatitis B core antibody and the occult hepatitis B infection among voluntary blood donors in chennai, India. *J Clin Diagn Res* 2012; **6**: 1710-1712 [PMID: 23373034 DOI: 10.7860/JCDR/2012/4826.2636]

37 **Makroo RN**, Chowdhry M, Bhatia A, Arora B, Rosamma NL. Hepatitis B core antibody testing in Indian blood donors: A double-edged sword! *Asian J Transfus Sci* 2012; **6**: 10-13 [PMID: 22623835 DOI: 10.4103/0973-6247.95043]

38 **Kleinman SH**, Kuhns MC, Todd DS, Glynn SA, McNamara A, DiMarco A, Busch MP. Frequency of HBV DNA detection in US blood donors testing positive for the presence of anti-HBc: implications for transfusion transmission and donor screening. *Transfusion* 2003; **43**: 696-704 [PMID: 12757519]

39 **El-Sherif AM**, Abou-Shady MA, Al-Hiatmy MA, Al-Bahrawy AM, Motawea EA. Screening for hepatitis B virus infection in Egyptian blood donors negative for hepatitis B surface antigen. *Hepatol Int* 2007; **1**: 469-470 [PMID: 19669344 DOI: 10.1007/s12072-007-9017-2]

40 **Allain JP**, Mihaljevic I, Gonzalez-Fraile MI, Gubbe K, Holm-Harritshøj L, Garcia JM, Brojer E, Erikstrup C, Saniewski M, Wernish L, Bianco L, Ullum H, Candotti D, Lelie N, Gerlich WH, Chudy M. Infectivity of blood products from donors with occult hepatitis B virus infection. *Transfusion* 2013; **53**: 1405-1415 [PMID: 23362802 DOI: 10.1111/trf.12096]

41 **Wang JT**, Lee CZ, Chen PJ, Wang TH, Chen DS. Transfusion-transmitted HBV infection in an endemic area: the necessity of more sensitive screening for HBV carriers. *Transfusion* 2002; **42**: 1592-1597 [PMID: 12473140]

42 **Satake M**, Taira R, Yugi H, Hino S, Kanemitsu K, Ikeda H, Tadokoro K. Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program. *Transfusion* 2007; **47**: 1197-1205 [PMID: 17581154 DOI: 10.1111/j.1537-2995.2007.01276.x]

43 **Arababadi MK**, Hassanshahi G, Yousefi H, Zarandi ER, Moradi M, Mahmoodi M. No detected hepatitis B virus-DNA in thalassemic patients infected by hepatitis C virus in Kerman province of Iran. *Pak J Biol Sci* 2008; **11**: 1738-1741 [PMID: 18819629]

44 **Singh H**, Pradhan M, Singh RL, Phadke S, Naik SR, Aggarwal R, Naik S. High frequency of hepatitis B virus infection in patients with beta-thalassemia receiving multiple transfusions. *Vox Sang* 2003; **84**: 292-299 [PMID: 12757503]

45 **Cabrerizo M**, Bartolomé J, De Sequera P, Caramelo C, Carreño V. Hepatitis B virus DNA in serum and blood cells of hepatitis B surface antigen-negative hemodialysis patients and staff. *J Am Soc Nephrol* 1997; **8**: 1443-1447 [PMID: 9294837]

46 **Goral V**, Ozkul H, Tekes S, Sit D, Kadiroglu AK. Prevalence of occult HBV infection in haemodialysis patients with chronic HCV. *World J Gastroenterol* 2006; **12**: 3420-3424 [PMID: 16733862]

47 **Siagris D**, Christofidou M, Triga K, Pagoni N, Theocharis GJ, Goumenos D, Lekkou A, Thomopoulos K, Tsamandas AC, Vlachojannis J, Labropoulou-Karatza C. Occult hepatitis B virus infection in hemodialysis patients with chronic HCV infection. *J Nephrol* 2006; **19**: 327-333 [PMID: 16874693]

48 **Yakaryilmaz F**, Gurbuz OA, Guliter S, Mert A, Songur Y, Karakan T, Keles H. Prevalence of occult hepatitis B and hepatitis C virus infections in Turkish hemodialysis patients. *Ren Fail* 2006; **28**: 729-735 [PMID: 17162434 DOI: 10.1080/08860220600925602]

49 **Fabrizi F**, Bunnapradist S, Lunghi G, Aucella F, Martin P. Epidemiology and clinical significance of hepatotropic infections in dialysis patients. Recent evidence. *Minerva Urol Nefrol* 2004; **56**: 249-257 [PMID: 15467503]

50 **Mina P**, Georgiadou SP, Rizos C, Dalekos GN, Rigopoulou EI. Prevalence of occult hepatitis B virus infection in haemodialysis patients from central Greece. *World J Gastroenterol* 2010; **16**: 225-231 [PMID: 20066742]

51 **Chemin I**, Zoulim F, Merle P, Arkhis A, Chevallier M, Kay A, Cova L, Chevallier P, Mandrand B, Trépo C. High incidence of hepatitis B infections among chronic hepatitis cases of unknown aetiology. *J Hepatol* 2001; **34**: 447-454 [PMID: 11322208]

52 **Bréchot C**, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Bréchot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"? *Hepatology* 2001; **34**: 194-203 [PMID: 11431751 DOI: 10.1053/jhep.2001.25172]

53 **Kannangai R**, Molmenti E, Arrazola L, Klein A, Choti M, Thomas DL, Torbenson M. Occult hepatitis B viral DNA in liver carcinomas from a region with a low prevalence of chronic hepatitis B infection. *J Viral Hepat* 2004; **11**: 297-301 [PMID: 15230851 DOI: 10.1111/j.1365-2893.2004.00502.x]

54 **Hassan ZK**, Hafez MM, Mansor TM, Zekri AR. Occult HBV infection among Egyptian hepatocellular carcinoma patients. *Virol J* 2011; **8**: 90 [PMID: 21371325 DOI: 10.1186/1743-422X-8-90]

55 **Demir M**, Serin E, Göktürk S, Ozturk NA, Kulaksizoglu S, Ylmaz U. The prevalence of occult hepatitis B virus infection in type 2 diabetes mellitus patients. *Eur J Gastroenterol Hepatol* 2008; **20**: 668-673 [PMID: 18679070 DOI: 10.1097/MEG.0b013e3282f55e1e]

**P-Reviewer:** Balaban YH, Ramos S, Sazci A, Zhang X **S-Editor:** Tian YL

**L-Editor: E-Editor:**

**Table 1 General, and epidemiological characteristics of included studies**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **OBI rate** ***n* (%)** | **Total number**  | **Age group** | **Location of the study** | **Studied population** | **Study period**  | **Ref.** |
| 0 (0) | 170 | Children | Lower Egypt | Healthy/Diabetic children | 2013-2014 | Elrashidy *et al*[10] |
| 16 (32 ) | 50 | Children  | Lower Egypt | HCV positive cancer  | 2011-2013 | Raouf *et al*[21] |
| 3 (1.85) | 162 | Adults | Lower Egypt | HCV  | ND | Kishk *et al*[22] |
| 1 (1.88) | 53 | Adults | Upper Egypt | Hematologic malignancy | 2010-2011 | Elkady *et al*[19] |
| 52 (1.64) | 3167 | Adults | Lower Egypt | HBD | ND | Said *et al*[34] |
| 21 (4.16) | 504 | Adults | Lower Egypt | HBD and HCV-BD | ND | El-Ghitany *et al*[31] |
| 7 (29.2) | 24 | Children  | Lower Egypt | CLD | ND | Youssef *et al*[23] |
| 6 (4.1) | 145 | Adults | Upper Egypt | HD  | ND | Abu El Makarem *et al*[18] |
| 25 (26.9) | 93 | Adult | Lower Egypt | HD | ND | Elgohary *et al*[20] |
| 26 (32.5) | 80 | Children | Lower Egypt | Thalasemics  | ND | Shaker *et al*[27] |
| 23 (38.3) | 60 | Adult | Lower Egypt | HCV | 2008-2009 | Selim *et al*[30] |
| 25 (62.5) | 40 | Adult | Lower Egypt | HCC | ND | Hassan *et al*[52] |
| 6 (3.9) | 155 | Adult | Lower Egypt | HCV | ND | Emara *et al*[32] |
| 5 (0.48) | 1021 | Adult | ND | HBD | 2007-2008 | Antar *et al*[25] |
| 16 (16) | 100 | Adult | Lower Egypt | HCV | 2005-2006 | El-Sherif *et al*[29] |
| 119 (58.3) | 204 | Adult | Lower Egypt  | CLD | ND | Youssef *et al*[26] |
| 9 (1.26) | 712 | Adult | Upper / lower Egypt | HBD | 2005 | El-Zayadi *et al*[33] |
| 21 (21) | 100 | Children | Lower Egypt | Hematologic malignancy and disorders | ND | Said *et al*[28] |
| 2 (1.3) | 150 | Adults | Lower Egypt | HBD | 1998-1999 | 1El-Sherif *et al*[39] |

1Data taken by direct contact with authors. ND: Not determined; OBI: Occult HBV; HBD: Healthy blood donors; HCV-BD: Blood donors positive for HCV; CLD: Cryptogenic liver disease; HD: Hemodialysis; HCV: Hepatitis C virus; HCC: Hepatocellular carcinoma; CC: Case control; CS: Cross sectional; HBV: Hepatitis B virus; PCR: Polymerase chain reaction.

**Table 2 Methods of hepatitis B virus DNA detection in included studies**

|  |  |  |  |
| --- | --- | --- | --- |
| **DNA limit of detection** | **PCR method** | **HBV DNA****detected in**  | **Ref.** |
| ND | Nested | Serum | Elrashidy *et al*[10] |
| ND | Real-time and Nested | Serum | Raouf *et al*[21] |
| ND | Real-time and Nested  | Serum | Kishk *et al*[22] |
| 20 IU/mL | Real-time | Serum | Elkady *et al*[19] |
| 3.8 IU/mL | Real-time | Serum  | Said *et al*[34] |
| 45 copies/mL | Semi-nested  | Serum | El-Ghitany *et al*[31] |
| 10 copies/mL | Real-time  | Serum | Youssef *et al*[23] |
| 6 IU/mL for real-time PCR | Nested and Real time for HBV-DNA-positive by nested PCR | Serum | Abu El Makarem *et al*[18] |
| ND | Real-time  | Serum | Elgohary *et al*[20] |
| ND | Real-time  | Serum | Shaker *et al*[27] |
| 45 copies/mL | Semi-nested | Serum | Selim *et al*[30] |
| ND | Nested | Liver tissue | Hassan *et al*[52] |
| 12 IU/mL | Real time  | Serum | Emara *et al*[32] |
| ND | Real-time | Serum | Antar *et al*[25] |
| 35 copies/mL | Real-time | Serum | El-Sherif *et al*[29] |
| ND | Nested | Serum | Youssef *et al*[26] |
| ND | Nested | Serum | El-Zayadi *et al*[33] |
| ND | Nested | Serum | Said *et al*[28] |
| ND | Nested | Serum | 1El-Sherif *et al*[39] |

1Data taken by direct contact with authors. ND: Not determined; ELISA: Enzyme-linked immunosorbent assay; ECLIA: Electrochemiluminescence; PCR: Polymerase chain reaction; HBV: Hepatitis B virus.